Flow Cytometry Use & Purchasing Trends : September 2020

Flow Cytometry Use & Purchasing Trends

September 2020 - Vol.9 No. 8 - Page #20

Article Category:

The promise of next-generation flow cytometry platforms including mass cytometry (CyTOF) and mass spectrometry-based digital imaging is substantial. With widespread use in immunophenotyping, analysis of hematopoietic neoplasias, diagnosis of primary immunodeficiencies, and for antibody screening and crossmatching, among other applications, flow cytometry is expected to continue to expand its clinical utility and utilization in clinical laboratories.

Utilization of flow cytometry has remained quite consistent over the past 5 years with just under 2 out of every 10 facilities taking advantage of this technology.

While its use in smaller facilities (<200 beds) is relatively scant, flow cytometry is commonly utilized in the largest facilities (400+ beds).

Beckman Coulter and BD Biosciences lead the pack, with Bio-Rad, Thermo Fisher Scientific, Luminex, and Sysmex Partec also well represented.

Click here to view a larger version of this Figure

Flow cytometry instrumentation delivers strong satisfaction, with 91% rating their vendors as excellent or good.

While most new adoptions will be concentrated in 400+ bed facilities, midsized hospitals expect to enjoy increasing adoption rates in the coming years.